Back to top

Analyst Blog

Smith & Nephew (SNN - Snapshot Report), the global medical technology business, declared the introduction of its latest offering, Regranex360. It is a comprehensive program devised to provide support to U.S. patients using REGRANEX Gel.

REGRANEX Gel is the first and only FDA-approved available platelet-derived growth factor (PDGF) therapy that can be used for the treatment of lower extremity diabetic neuropathic ulcers.

Regranex360 is a full service online portal that seeks to simplify the previous authorization and product acquisition process. The patient-friendly portal offers patients the scope to receive advice from a care coordinator via phone throughout the entire course of the therapy. In addition, respective patient care coordinators will contact their patients to schedule delivery, provide valuable education and resolve doubts related to treatment.

Moreover, patients are also given a chance to find answers to their queries using the Regranex360 hotline during their course of the therapy. Such specialized services will not only make the online portal customer-friendly and popular, but will also help it to adhere and comply with the REGRANEX Gel.

Regranex360 is simple to use and access. Following the submission of the enrollment forms by the clinicians either through Regranex360.com or via fax, the portal starts the process of obtaining the authorization approval. The prescription is then sent to an appropriate pharmacy.

Besides the Regranex360 program, Smith & Nephew Biotherapeutics has also introduced a new REGRANEX Gel Web site which highlights the features of the product including clinical research, complemented by a dosing calculator and additional tips for patients.

The new offering from Smith & Nephew Biotherapeutics reflects the commitment of the company to offer evidence-based biologic therapeutics. It is believed to be one of the best-in-class providers of patient support programs, designed especially for the wound care market. The company’s online portal is expected to streamline and improve the REGRANEX Gel patient experience, going forward.

SNN currently carries a Zacks Rank #3 (Hold). Other stocks that are worth a look include Bio-Rad Laboratories, Inc. (BIO - Snapshot Report) carrying a Zacks Rank #1 (Strong Buy), and Boston Scientific Corp. (BSX - Analyst Report) and ResMed Inc. (RMD - Analyst Report), each carrying a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%